Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01051609 · ClinicalTrials.gov registry record
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
A clinical trial, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- 27
- Enrollment target
NCT01051609: Completed study, sponsored by Jonsson Comprehensive Cancer Center.
NCT01051609 is a clinical trial that has completed, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01051609 has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to compare pre and post Aromatase Inhibitor (AI) treatment serological markers of inflammation and assess for correlation with AI-MS.
Interventions
- OTHER Blood Collection
- BEHAVIORAL Surveys
- OTHER History and Physical Exam
- OTHER Grip Strength Measurement
- PROCEDURE Ultrasound of Hand/Wrist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-05 |
What the finished NCT01051609 record still lists
NCT01051609 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 5 interventions - of which Blood Collection is the first listed.
NCT01051609 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01051609 about?
NCT01051609 is a clinical study titled "Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients". The purpose of this study is to compare pre and post Aromatase Inhibitor (AI) treatment serological markers of inflammation and assess for correlation with AI-MS.
What is the current status of trial NCT01051609?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2010-05.
What interventions are being tested in trial NCT01051609?
The interventions under investigation include: Blood Collection (OTHER), Surveys (BEHAVIORAL), History and Physical Exam (OTHER), Grip Strength Measurement (OTHER), Ultrasound of Hand/Wrist (PROCEDURE).
Who is sponsoring clinical trial NCT01051609?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia